The APAC Market and Who Already Owns It

Spatial genomics and transcriptomics sit at an awkward commercial size. The techniques are scientifically central to oncology, immunology, neuroscience and developmental biology, yet the money that changes hands is still measured in hundreds of millions, not billions. Asia Pacific is projected to reach revenue of US$139.0 million by 2030 at a 12.2% CAGR from 2024 to 2030, according to Grand View Research, 2024. Narrowing to spatial transcriptomics alone, the region generated US$51.2 million in 2024 and is forecast to grow at 16.4% a year to 2033 (Grand View Research, 2024).

Globally, MarketsandMarkets puts the category at US$995.7 million by 2029 on a 12.4% CAGR (MarketsandMarkets, 2025), while Polaris Market Research sizes 2025 at US$745.38 million and names Asia Pacific the fastest-growing region at a 14.20% CAGR for 2026 to 2034 (Polaris Market Research, 2026). Those two numbers disagree by a factor of three, and the disagreement matters: the lower estimates count instruments and consumables, the higher ones fold in services, software and sometimes adjacent single-cell revenue. If your plan quotes a market size, it needs to say which definition it is using, because an investor who has read two reports will notice.

Consumables carry the revenue, software carries the growth

Within Asia Pacific, consumables were the largest revenue-generating product category in 2023, while software is the fastest-growing segment through the forecast period. That split has a direct consequence for how you write your business model. A consumables-heavy market means a service provider's cost of goods is dominated by someone else's reagent price list and moves when that supplier reprices. A software-led growth curve means the defensible part of your business is probably the analysis layer, not the bench.

Demand drivers in the region are specific rather than generic. Government investment in biotechnology, rising oncology burden and national precision-medicine programmes are doing the work. Australia's Medical Research Future Fund runs a Genomics Health Futures Mission investing A$500.1 million over ten years from 2018-19, with a recent tranche of A$50 million across 30 projects (Australian Department of Health). India runs the Genome India Project. Japan's AMED funds translational genomic medicine. Singapore's PRECISE programme built the SG100K national cohort. Each of these is a named, budgeted buyer of spatial work, and naming them in your plan beats asserting that the sector is growing.

The competitive picture a new entrant actually faces

Three facts set the shape of competition. First, 10x Genomics reported FY2025 revenue of US$642.8 million, with Q4 2025 spatial consumables of approximately US$41.0 million, up 14% year over year (10x Genomics, 2026). Spatial is growing but it is a minority of even the category leader's revenue, which tells you the installed base is still small and your addressable customer list is countable.

Second, consolidation has already happened on the imaging side. Bruker acquired substantially all of NanoString's assets, including the nCounter, GeoMx, CosMx and AtoMx product lines, for approximately US$392.6 million, closing in May 2024 (GEN, 2024). A new service lab is therefore choosing between two well-capitalised platform vendors plus Vizgen's MERSCOPE line, and your reagent supply risk is concentrated.

Third, and most relevant for an APAC business, there is a regional platform. BGI's STOmics division markets Stereo-seq, which resolves to spots 220 nm in diameter, and STOmics with MGI launched a Spatial Omics Grant programme in November 2025 aimed at the APAC region including Japan, South Korea, Southeast Asia and the Middle East. A provider positioned on Stereo-seq can often undercut a Visium or Xenium shop on price per section while making a genuine resolution claim, and that is a real competitive wedge rather than a marketing one.

Capital is available for differentiated technology but not for undifferentiated service. Stellaromics closed an US$80 million Series B for its Pyxa 3D spatial platform and Moleculent closed a US$25 million Series A in June 2024 (Inside Precision Medicine). Those rounds went to platform IP. Service businesses in this niche are funded by equipment finance, grants and revenue, which changes what your plan needs to prove.

If your venture sits closer to the analysis end, the economics and the plan structure differ enough that our bioinformatics service business plan template is the better starting point, and sample-prep-heavy models overlap heavily with our Asia Pacific single-cell analysis template.

Questions Lenders and Buyers Ask First

These are the questions that come up in the first meeting, whether the counterparty is a principal investigator deciding where to send tissue or a credit officer deciding whether to finance an instrument. Answer them in the plan and you shorten every conversation that follows.

What is the difference between spatial genomics and spatial transcriptomics?

Spatial transcriptomics measures RNA while preserving the position of each measurement within the tissue section. Spatial genomics is the broader umbrella, covering spatially resolved DNA, RNA, protein and epigenetic readouts. Commercially the distinction matters because the two terms attract different buyers: transcriptomics buyers are mostly discovery researchers, while the wider spatial genomics framing pulls in translational and clinical programmes with longer sales cycles and accreditation expectations. Most APAC service businesses sell transcriptomics first and add protein co-detection second.

How much does spatial transcriptomics cost per sample?

Published academic core rates are the clearest public anchor. Visium HD runs US$12,887.70 per slide at the Dartmouth genomics shared resource and US$14,000 per slide at the Brigham Center for Cellular Profiling, while the University of Mississippi Medical Center lists Visium HD at US$3,100 per sample. Yale's microarray resource listed US$2,141 per 6.5 mm CytAssist section and US$4,151 per 11 mm section as of July 2025. On the imaging side, Xenium v1 at 345 or 750 genes is US$11,000 per sample at the University of Pittsburgh core and Xenium 5K Prime is US$23,500 per sample; Brigham lists US$7,500 per Xenium V1 slide and US$12,000 per Xenium 5K slide. The spread is not inconsistency: some rates are per slide with multiple sections, some are per sample, and some include library prep and sequencing while others do not. Low-plex assays can land in the US$1,000 to US$2,000 per sample range, and NanoString-style 1,000-plex engagements have historically started around a US$10,000 minimum.

Which platform should a new lab buy?

Decide by the assay you will sell most of, not by specification sheets. Sequencing-based workflows such as Visium HD and Stereo-seq are whole-transcriptome and forgiving on panel design, which suits discovery customers and unknown targets. Imaging-based in-situ workflows such as Xenium, CosMx and MERSCOPE give single-cell or subcellular resolution on a defined panel, which suits translational and pathology-adjacent work where the targets are already known. A first instrument should be whichever one your three most likely anchor customers already publish with, because you are buying their validated protocols along with the hardware.

Can tissue or sequence data leave China for analysis?

Not freely. Under the Implementation Rules for the Regulations on Management of Human Genetic Resources, effective 1 July 2023, foreign parties must obtain prior approval to use Chinese human genetic resources in international collaboration or to transfer HGR materials or information abroad, and a Chinese entity must notify the HGR administration when sharing HGR data with a foreign party (Ropes & Gray, 2023). "Foreign party" is defined broadly enough to catch PRC entities under foreign actual control, including VIE structures. Most regional providers answer this by keeping an in-country bench or an in-country partner for Chinese samples and routing only approved, aggregated outputs offshore. That operating choice belongs in the operations plan, not in a footnote.

Is spatial work clinical or research only?

Overwhelmingly research today, with a growing translational edge. The clinical path runs through laboratory developed tests rather than kit approvals, and that path changed twice recently: FDA's May 2024 final rule extending device regulation to LDTs was vacated by a federal court in March 2025, and FDA reverted the regulatory text in September 2025 (Faegre Drinker, 2025). For a plan written now, that means a US clinical offering is a CLIA and state-law exercise, not an FDA submission.

How many customers does a lab like this need?

Fewer than founders expect, which is both the good news and the risk. At a blended US$13,000 per run, a lab needs roughly 11 billable runs a month to clear US$1.7 million of annual revenue, and in practice four to six institutional accounts generate most of that. Concentration is the real exposure: losing one anchor laboratory can remove a third of throughput in a quarter. Lenders ask for named pipeline, not a total addressable market figure.

Capital Requirements: Three Build Routes, Costed

There is no single startup cost for a spatial omics business because there are three genuinely different businesses hiding behind the same keyword. Pick one before you build a forecast. Our composite ranges below reflect Avvale modelling against published instrument and core-facility rates, and they are presented as planning estimates rather than quotations.

Route A: analysis and project management, no bench

You sell experimental design, sample routing to a partner lab and the bioinformatics. Capital requirement is US$185,000 to US$320,000 (£145,000 to £252,000), almost all of it people, compute and the working capital to pre-pay a partner lab before a client invoice settles. Gross margin is the highest of the three routes at 68% to 82%, and the business can reach breakeven inside nine months. The weakness is that your cost base is a third party's price list and your differentiation is a methods document, both of which are copyable.

Route B: sequencing-based wet lab

You run tissue handling, sectioning and library preparation for Visium HD or Stereo-seq, then send libraries to a sequencing partner. Capital requirement is US$420,000 to US$760,000 (£330,000 to £598,000). The step change versus Route A is cryostat, imaging, containment fit-out and a meaningful consumable float. This is the most common APAC starting point because it avoids a single large instrument purchase while still owning the part of the workflow clients find hardest.

Route C: imaging-based in-situ lab

You buy and run your own in-situ instrument. Capital requirement is US$900,000 to US$1,450,000 (£708,000 to £1,140,000), dominated by a US$295,000 to US$450,000 instrument and the reagent float behind it. Route C gives the strongest technical moat and the worst cash profile. It is financeable precisely because the asset is collateral, which is why most Route C businesses are built on equipment finance rather than equity.

Funding routes that actually close

For a US-registered entity, SBA 7(a) is the workhorse. Testing laboratories fall under NAICS 541380, where the small-business size standard is US$19 million in average annual receipts (SAM Search, NAICS 541380), which keeps essentially any new spatial omics services arm comfortably inside eligibility. Programme-wide, 65,154 7(a) loans were approved in FY2025 for US$32.43 billion, an average of US$497,789, but the median is US$195,000, so the mean runs about 2.7 times the median. Build your ask against the median, not the average, because a US$480,000 request sits above the typical approved loan and will be underwritten accordingly: expect a personal guarantee, 10% to 20% equity injection and a collateral conversation about the instrument.

For a UK-registered arm, the Start Up Loans scheme offers up to £25,000 per founder at 6% fixed with free mentoring. That is a founder-level product, not a lab-funding product, and it is best used for pre-revenue setup costs alongside Innovate UK grant routes and R&D tax relief on qualifying work.

Across Asia Pacific, equipment finance and grant co-funding do most of the heavy lifting. A Route C instrument is a financeable asset with a four to five year term, and national programmes including Australia's MRFF Genomics Health Futures Mission, Japan's AMED and Singapore's precision-medicine funding can underwrite validation work that no lender will touch. Vendor grant programmes matter too: the STOmics and MGI Spatial Omics Grant launched in November 2025 was explicitly aimed at APAC researchers, and a provider that helps clients win those grants buys itself a pipeline.

If the gap in your plan is the forecast rather than the narrative, our market research and content package covers the sizing and the written plan, while the bespoke business plan adds a five-year model built around the utilisation floor described in the next section.

Instrument, Consumable and Compute List

This is the list a lender's technical reviewer will ask for and the list most first-draft plans compress into one line called "equipment". Named platforms below are the commercially available options as of 2026; prices are planning ranges benchmarked to published core-facility rate cards rather than vendor quotations, and you should confirm current pricing with each supplier before committing numbers to a forecast.

Spatial platforms, by workflow type

• 10x Genomics Visium HD (sequencing-based, whole transcriptome): consumables published at US$12,887.70 per slide at Dartmouth and US$14,000 per slide at Brigham; CytAssist instrument required for FFPE workflows
• 10x Genomics Xenium Analyzer (imaging-based in situ): instrument in the US$295K to US$450K planning band; per-sample rates published at US$11,000 for v1 345/750-plex and US$23,500 for 5K Prime at the University of Pittsburgh
• Bruker Spatial Biology CosMx SMI (imaging-based): no public list price, quote-request model only; the platform supports spatially resolved quantitation of more than 1,000 RNA and over 64 protein targets, with CosMx Whole Human Transcriptome launched in 2025
• Bruker GeoMx DSP (region-of-interest profiling): the pragmatic entry point for pathology-led labs that want spatial data without single-cell segmentation
• Vizgen MERSCOPE and MERSCOPE Ultra (imaging-based MERFISH): quote-request sales model, no published price list
• BGI STOmics Stereo-seq (sequencing-based, sub-micron): 220 nm spot diameter, roughly a tenfold resolution increase over Visium HD; the regional cost-leader option for APAC providers
• Stellaromics Pyxa (3D spatial): newer entrant, backed by an US$80 million Series B, worth tracking rather than buying first

Supporting bench equipment

• Cryostat with anti-roll plate: US$28,000 to US$65,000. Fresh-frozen spatial work lives or dies on section quality, and a shared departmental cryostat is the most common cause of failed runs in a young lab
• Rotary microtome plus water bath for FFPE: US$8,000 to US$22,000
• Brightfield and fluorescence slide imager: US$55,000 to US$140,000, needed for H&E registration and QC imaging
• Thermocycler, qPCR and fragment analyser for library QC: US$35,000 to US$70,000 combined
• Minus-80 freezers with alarm and backup, plus liquid nitrogen storage: US$18,000 to US$45,000
• UPS and generator transfer for the instrument and freezers: US$12,000 to US$40,000, non-negotiable in markets with grid instability
• Class II biosafety cabinet and BSL-2 containment works: US$25,000 to US$90,000 depending on the shell you start with
• RNase-free dedicated prep room with controlled access: fit-out cost, but also an accreditation expectation

Compute, storage and software

Spatial runs are among the heaviest data generators in applied genomics, and this is where plans most often under-budget. Each imaging-based run can produce multiple terabytes of raw image data before segmentation.

• GPU workstation or server for segmentation and registration: US$18,000 to US$55,000
• Tiered storage, 200TB usable with archive tier: US$28,000 to US$63,000 in year one, on-premise or reserved cloud
• Vendor pipelines: Space Ranger and Xenium Ranger for 10x workflows, AtoMx for Bruker spatial data
• Open analysis stack: Seurat, Scanpy, Squidpy, Giotto and SpatialData for downstream work, plus SpaceRanger-compatible QC reporting
• LIMS and quality management: a sample-tracking system with audit trail from day one, because chain of custody is an accreditation requirement and retrofitting it is painful
• Interactive data delivery: clients increasingly expect a browsable viewer rather than a folder of files, and this is a genuine differentiator for a services business

Reagents account for the large majority of the per-section charge in published core costings, which is the single most important line in your working-capital plan. A lab that finances an instrument and then cannot fund three months of reagents has bought a very expensive paperweight.

Pricing and Where Margin Actually Sits

Spatial omics service pricing has an unusual property: the comparison set is public. Academic core facilities publish rate cards, and your prospective customers read them. That sets a visible ceiling. Cores typically charge external academic users roughly 1.6 times their internal rate and commercial users roughly 1.8 times, so a private provider is usually selling into the gap between the internal academic rate and the commercial core rate.

The four revenue lines worth building

• Per-run wet-lab service: the volume line. Blended US$9,000 to US$16,000 per run depending on platform and plex. Gross margin 38% to 62% after reagents and slide costs
• Analysis and reanalysis: the margin line. US$3,500 to US$12,000 per project at 68% to 82% gross, and it is sellable to clients who ran their samples elsewhere
• Study design and feasibility: the trust line. US$2,000 to US$6,000, often discounted or free, and it is how you win the per-run work. Treat it as a sales cost with a revenue label
• Retained programme work: the valuation line. A pharmaceutical or biotech client on a 12-month retainer at US$18,000 to US$45,000 a month turns a project shop into a business with forward revenue

A worked example you can argue with

Take a Singapore-registered provider running one Xenium Analyzer, sized at 11 billable runs a month at steady state.

• Revenue: 7 commercial runs at US$15,500 plus 4 academic runs at US$9,800 equals US$147,700 a month
• Reagents and slides: US$5,900 per run across 11 runs equals US$64,900, leaving US$82,800 gross, 56%
• Instrument depreciation: US$7,900 a month on a four-year straight line
• Scientific payroll: 3.2 FTE at US$31,400 a month fully loaded
• Lab occupancy and utilities: US$9,100 a month
• Compute and storage: US$4,300 a month
• Quality system and accreditation amortisation: US$2,600 a month
• Operating profit: US$27,500 a month, 18.6% net

Now run it at seven runs a month instead of eleven. Revenue falls to roughly US$89,000, gross falls to about US$47,700, and fixed costs of US$55,300 put the same lab about US$6,200 under water every month. Nothing about the price list changed. The entire result sits in utilisation, and that is why a serious plan states a breakeven run count and shows how the pipeline supports it. Investors in this niche do not interrogate the price per sample. They interrogate the denominator.

Where margin leaks

Three leaks recur. Failed runs, because a poor section consumes full reagent cost and produces no invoice, which is why section QC gates belong in the operations plan with a target failure rate under 8%. Scope creep on analysis, because "a bit more bioinformatics" is unbilled time at the highest-cost headcount you have. And storage, because every completed project leaves terabytes behind and a data retention policy with a client-funded archive tier is the difference between a cost that grows linearly and one that grows quadratically.

Country by Country: Demand and Cost to Serve

"APAC" is a reporting convenience, not a market. The jurisdictions inside it differ more on sample movement and reimbursement than on science, and a plan that treats the region as one territory will be picked apart by anyone who has operated in two of them. Treat the notes below as a planning map to localise, then verify the current position in each market with local counsel before you commit.

China

The largest research volume and the hardest operating constraint. Cross-border transfer of human genetic resources needs prior approval, foreign-controlled entities are caught by a deliberately broad definition, and primary oversight moved from the Ministry of Science and Technology to the National Health Commission, which issued updated guidelines in April 2025. Practical implication: an in-country bench or a licensed local partner, with data handling designed around approval rather than around convenience. Domestic platform supply via BGI STOmics also makes China the one market where a Stereo-seq-first strategy has a supply-chain advantage as well as a price advantage. Suzhou BioBay and the Shanghai Zhangjiang cluster are the usual landing points.

Japan

High willingness to pay, long qualification cycles, strong preference for established vendors and published validation. AMED-funded translational programmes are the realistic entry wedge, and a Japanese-language methods and reporting layer is not optional if you intend to sell to hospital-affiliated laboratories. Expect the longest sales cycle in the region and the best retention once you are in.

Singapore

The natural regional hub for a services business: English-language contracting, dense biotech cluster at Biopolis, and a regulator whose standards travel. IVDs are regulated as medical devices requiring HSA evaluation and registration before supply or use, and HSA is recognised by WHO as a stringent regulatory authority for high-risk IVDs (Singapore MOH), which means a Singapore registration is useful as a reference approval elsewhere. The competitive catch is that A*STAR's Genome Institute of Singapore runs a Spatial and Single Cell Genomics Platform that is a 10x Genomics Certified Service Provider for spatial gene expression, so you are competing with a well-funded national core on your own doorstep. Differentiate on turnaround, commercial contracting and analysis depth rather than on capability claims.

India

Fastest-growing demand base, most price-sensitive buyers. IVDs sit under the Medical Devices Rules 2017 with CDSCO's risk-based classification updated in 2023, and NABL accreditation, which covers Genetics among its medical testing disciplines, is in practice the precursor to regulator and statutory recognition (Journal of Applied Laboratory Medicine, 2026). The Genome India Project has built both capability and expectation. A viable India model usually prices 35% to 50% below Singapore or Japan and recovers it on volume plus local reagent sourcing.

Australia and New Zealand

Small volume, excellent funding. The MRFF Genomics Health Futures Mission's A$500.1 million ten-year commitment and its A$50 million across 30 projects mean grant-funded spatial work is genuinely available, and NATA accreditation plus a tight academic network makes the market easy to cover from one site. Melbourne's Parkville precinct and Sydney's Camperdown precinct account for a large share of demand, and local providers such as SA Genomics already offer spatial transcriptomics services.

South Korea and Taiwan

Strong instrumentation budgets and dense oncology research, with a preference for in-country service and rapid turnaround. Both were named territories in the STOmics and MGI APAC grant programme launched in November 2025, which is a useful signal about where platform vendors expect growth.

Southeast Asia beyond Singapore

Malaysia, Thailand, Indonesia and Vietnam are early but moving, usually served from a Singapore bench with local sample-intake partners. The binding constraint is cold-chain logistics, not demand. Budget realistically for validated courier routes, temperature logging and customs documentation for biological material, because a plan that assumes same-week sample arrival across six countries will not survive its first quarter.

Accreditation, Consent and Cross-Border Data

Three regulatory layers apply to this business and they are often confused in draft plans. Layer one is laboratory accreditation, which governs whether your results can be trusted. Layer two is human tissue and consent law, which governs whether you may hold the sample at all. Layer three is data and export control, which governs where the sequence can go. A plan needs all three, with the right agency names.

United States

• CLIA certificate (high complexity): issued under CMS oversight. Most molecular genetic tests classify as moderate or high complexity, and CLIA has no genetics-specific specialty, so a spatial assay offered clinically must satisfy high-complexity personnel, proficiency-testing and biennial-inspection requirements (CMS, How to Obtain a CLIA Certificate). Budget US$5,000 to US$25,000 for certification and the first survey cycle, and four to nine months of elapsed time
• State licensure: additional and separate. New York State operates its own LDT approval programme, which is the strictest in the country and should be assumed to add months
• LDT status: FDA's 2024 LDT final rule was vacated in March 2025 and the regulatory text reverted in September 2025, returning LDTs to regulation as clinical laboratory services under CLIA and state law (Faegre Drinker, 2025). Any plan still budgeting an FDA device submission for a spatial LDT is costing a pathway that no longer applies
• IRB approval and consent: required for human-subject research use, with consent language that explicitly covers spatial profiling and secondary analysis

United Kingdom

• UKAS accreditation to ISO 15189:2022: there is no published universal fee schedule, and cost scales with scope breadth, assessment days, technical assessors and site count. UKAS indicative costings for a small scope show an annual accreditation fee of £2,762 and a total around £10,218.75 a year including a witnessed assessment (UKAS accreditation costs). Expect 12 to 24 months from application to first scope grant
• Human Tissue Authority licence: required to store relevant human material for a scheduled purpose, with a named Designated Individual. UK genomic laboratories are assessed by both UKAS and the HTA (Manchester University NHS Foundation Trust, NWGLH)
• Research Ethics Committee approval via HRA for research involving NHS patients or tissue
• MHRA and UKCA: engaged only if you sell an assay as a kit rather than deliver it as a service. The service-versus-product boundary is the most commercially consequential line in a UK spatial plan
• Scope discipline: listing every assay in a first accreditation application multiplies assessment days and fees. Accredit the two assays that carry revenue, then extend scope

Asia Pacific jurisdictions

• China: Implementation Rules for the Regulations on Management of Human Genetic Resources, effective 1 July 2023. Prior approval needed for foreign use of Chinese HGR in international collaboration and for transfer of HGR materials or information abroad; notification needed when a Chinese entity shares HGR data with a foreign party, with a carve-out where approval or a recordation filing already covers the collaboration and the parties contract to use the data jointly. Oversight now sits with the NHC (Covington, 2025)
• Singapore: HSA evaluation and registration before an IVD may be supplied or used
• India: Medical Devices Rules 2017 with CDSCO's 2023 risk-based IVD classification; NABL accreditation covering Genetics, with ICMR involvement in certain import no-objection certificates
• Australia: NATA accreditation for pathology, with TGA engagement where an in-house IVD is involved
• Regional LDT patchwork: APACMed's January 2025 LDT white paper documents how differently laboratory developed tests are treated across the region (APACMed, 2025). One regional assay menu rarely clears every market, and your plan should say which markets the first menu is for

Fees, timelines and classifications in this section change. Verify each one with the named agency before it becomes a line in your financial model, and date the assumption in the plan so a reviewer can see when you checked.

Terminology Your Investor Will Test

This niche punishes imprecision. A credit officer may not know the biology, but a technical reviewer or a scientific advisor on an investment committee will, and using these terms loosely is the fastest way to lose a room. Define them correctly in the plan's appendix and use them consistently in the body.

• Plex: the number of distinct targets measured in one run. Panel size drives both reagent cost and price, and "high-plex" with no number attached is a red flag in a forecast
• Sequencing-based versus imaging-based: the primary architectural split. Sequencing-based methods capture transcripts on a barcoded surface and read them out on a sequencer; imaging-based in-situ methods detect targets directly in the tissue by cyclic imaging. The two have different cost structures, different failure modes and different customers
• Spot, bin and cell segmentation: a spot or bin is a spatial capture unit; segmentation is the computational step that assigns signal to individual cells. Resolution claims are meaningless without saying whether they refer to capture unit size or to segmented single cells
• Deconvolution: inferring the cell-type composition of a capture unit that contains more than one cell. Required for spot-based platforms, and a common hidden cost in analysis scope
• FFPE versus fresh frozen: formalin-fixed paraffin-embedded tissue is what hospitals have in their archives; fresh frozen gives better RNA quality. FFPE compatibility determines whether you can sell into biobank and retrospective-cohort work, which is where the volume is
• RIN and DV200: RNA integrity metrics used to accept or reject a sample before it consumes reagents. Your acceptance thresholds belong in the operations plan, because they are what keeps the failure rate down
• CytAssist: the 10x instrument used to transfer tissue sections onto a Visium slide in FFPE workflows. A Visium FFPE service without it is not a complete workflow
• Multimodal or co-detection: measuring RNA and protein in the same section. The most reliable upsell in this market, and worth a separate price line
• Human genetic resources (HGR): the regulatory category under Chinese law covering human genetic materials and the data derived from them. If your plan mentions China, this term should appear
• LDT: laboratory developed test, an assay designed, manufactured and used within a single laboratory. The regulatory route for clinical spatial assays in the US, and a category treated inconsistently across Asia Pacific

Inside a Finished Plan

Here is an extract from the executive summary of a spatial omics services plan written to the structure in our template, so you can see the level of specificity that gets a plan read twice:

Illustrative extract built to our template structure. Company name and figures are composites created for this example.

What the Template Gives You

Every Avvale business plan template ships with these sections, pre-structured so you are filling in a spatial omics argument rather than inventing a document outline:

• Executive Summary — the platform choice, the utilisation floor and the funding ask in the first 300 words
• Company Overview — entity structure across jurisdictions, which matters more here than in most sectors because sample and data rules follow the entity
• Industry Analysis — market sizing with scope stated, the platform field mapped, and the regulatory layers that gate your menu
• Customer Analysis — named institutional accounts, grant cycles and the procurement route into each
• Competitor Analysis — academic cores, regional CROs and global service providers mapped on price, turnaround and accredited scope
• Marketing Plan — conference presence, methods publication, co-authorship and the grant-support motion that actually generates pipeline in this field
• Operations Plan — intake criteria, QC gates, failure-rate targets, data retention and the chain-of-custody record an assessor will ask for
• Management Team — the pathologist plus computational biologist pairing lenders look for, and the advisory bench that substitutes for track record

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements. For a spatial omics build we set the model up around run volume so that the breakeven run count, not a revenue growth percentage, is the driver you flex.

Related templates worth reading alongside this one: the broader genomics business plan template if your scope extends past spatial, and the AI in genomics business plan template if the analysis layer is the product. If you would rather not write any of it, our business plan writers handle the whole document.

Frequently Asked Questions